The Hair Loss Encyclopedia

Search

for
Search:

GlossaryNivolumab

immunotherapy drug that helps immune system attack cancer cells

Nivolumab, also known by the brand name Opdivo, is an immunotherapy drug used to treat various types of cancer. It works by blocking a protein called PD-1 on the surface of T-cells, which helps the immune system recognize and attack cancer cells more effectively.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 82 results

research Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review

10 citations , January 2021 in “Annals of dermatology/Annals of Dermatology”

Nivolumab can cause hair loss as a rare side effect.

research Anti-Programmed Cell Death Protein 1-Induced Lichenoid Changes of the Nail Unit: Histopathologic Description

12 citations , March 2021 in “JAAD Case Reports”

Nail changes from immunotherapy can be managed without stopping cancer treatment.

research Eosinophilic Folliculitis of the Scalp Associated with PD-1/PDL1 Inhibitors

9 citations , April 2020 in “Journal of Cosmetic Dermatology”

Immune checkpoint inhibitors can cause scalp inflammation and hair follicle issues.

Resolution of Paraneoplastic Alopecia Areata Following Nivolumab in a Patient With Metastatic Melanoma

research Resolution of Paraneoplastic Alopecia Areata Following Nivolumab in a Patient With Metastatic Melanoma

1 citations , June 2023 in “JAAD case reports”

Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.

Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy

research Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy

November 2022 in “Journal of the Endocrine Society”

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

View more "nivolumab" in research →

Community Join

0 / 0 results

— no results